Beyond Air, Inc. (XAIR) — 10-Q Filings
All 10-Q filings from Beyond Air, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Beyond Air Narrows Losses, Boosts Revenue Amid Strategic Reorganization
— Nov 10, 2025 Risk: high
Beyond Air, Inc. (XAIR) reported a net loss of $8.258 million for the three months ended September 30, 2025, a significant improvement from the $14.029 million -
Beyond Air Posts No Revenue, Expands Ventures Amidst Losses
— Aug 12, 2025 Risk: high
Beyond Air, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with the prior year's quarter. The company's net loss for the three months -
Beyond Air Files 10-Q for Period Ending Dec 31, 2024
— Feb 10, 2025 Risk: medium
Beyond Air, Inc. filed its 10-Q for the period ending December 31, 2024. The company, formerly known as AIT Therapeutics, Inc. and KokiCare, Inc., is incorporat -
Beyond Air Files 10-Q for Q2 2024
— Nov 12, 2024 Risk: medium
Beyond Air, Inc. filed its 10-Q for the period ending September 30, 2024, reporting on its financial performance. The company, formerly known as AIT Therapeutic -
Beyond Air, Inc. Files Q2 2024 10-Q
— Aug 6, 2024 Risk: medium
Beyond Air, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as AIT Therapeutics, Inc. and KokiCare, Inc., is involved in th -
Beyond Air, Inc. Files 10-Q for Period Ending December 31, 2023
— Feb 12, 2024 Risk: low
Beyond Air, Inc. (XAIR) filed a Quarterly Report (10-Q) with the SEC on February 12, 2024. Beyond Air, Inc. filed its 10-Q report for the period ending December
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX